Skip to main content
. 2023 Jul 25;12(15):e030603. doi: 10.1161/JAHA.123.030603

Figure 3. Potential treatment targets for clonal hematopoiesis‐related inflammation.

Figure 3

Depending on the clonal hematopoiesis driver mutation involved, therapeutic targets upstream of proinflammatory cytokines may be targeted by JAK2 inhibitors (eg, in case of the gain‐of‐function mutation JAK2 V617F ) or by NLRP3 inhibitors (eg, in case of a TET2 or a DNMT3A mutation). Downstream of the inflammasome proinflammatory cytokines, such as interleukin‐1, interleukin‐6, and tumor necrosis factor, are a potential target of clonal hematopoiesis‐mediated inflammation. Purple indicates a mutated cell, and light blue indicates a normal cell. IL indicates interleukin; IL‐1, interleukin‐1; IL‐1R, interleukin‐1 receptor; IL‐6, interleukin‐6; IL‐18, interleukin‐18; NLRP3, NLR family pyrin domain containing 3; and TNF‐α, tumor necrosis factor‐α.